---
layout: default
title: Pembrolizumab
parent: 僅模型預測 (L5)
nav_order: 341
evidence_level: L5
indication_count: 10
---

# Pembrolizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pembrolizumab: From Oncology (PD-1 Checkpoint Inhibitor) to Gingival Fibromatosis

## One-Sentence Summary

Pembrolizumab is a PD-1 immune checkpoint inhibitor whose established biological context (per the literature attached to this evidence pack) is oncology, including indications such as non-small cell lung cancer and urothelial carcinoma. The TxGNN model's top-ranked prediction is **Gingival Fibromatosis**, but this evidence pack currently contains **0 clinical trials and 0 publications** supporting the link, and the model's own mechanistic rationale states there is no known biological relationship between PD-1 blockade and this condition.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in evidence pack (`taiwan_regulatory.licenses` and `drug.original_indications` are both empty; contextual literature references PD-1 checkpoint blockade in oncology, e.g., NSCLC, urothelial carcinoma) |
| Predicted New Indication | Gingival Fibromatosis |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 (model prediction only — no clinical trials or literature) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Pembrolizumab in this evidence pack (`original_moa` is flagged as a data gap). Based on the contextual information present elsewhere in the pack, Pembrolizumab is a monoclonal antibody targeting the PD-1 immune checkpoint, with established oncology use (referenced indications include non-small cell lung cancer and urothelial carcinoma). Its known mechanism works by blocking the PD-1/PD-L1 interaction to reactivate cytotoxic T-cell–mediated antitumour immunity.

Gingival fibromatosis, in contrast, is a benign hereditary connective-tissue disorder (often associated with genes such as *SOS1*), driven by fibroblast proliferation and extracellular matrix accumulation. It is not a malignancy and does not involve tumour immune evasion — the biological process that PD-1 checkpoint blockade is designed to reverse.

The evidence pack's own mechanistic assessment is explicit on this point: the high TxGNN score is attributed to graph-embedding similarity within the knowledge graph rather than to any validated pharmacological or mechanistic relationship. No clinical trials, literature, or mechanistic studies support this candidate, and no biological rationale connecting PD-1 blockade to gingival fibromatosis pathology has been identified.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Cytotoxicity

Pembrolizumab is an antineoplastic agent (PD-1 immune checkpoint inhibitor), based on the oncology context referenced throughout this evidence pack's literature (e.g., NSCLC, urothelial carcinoma treatment settings).

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (immune checkpoint inhibitor — anti-PD-1 monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions (no myelosuppression data in this evidence pack) |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions (no emetogenicity data in this evidence pack) |
| Monitoring Items | Endocrine function (thyroid, pituitary-adrenal axis) — supported by a case report elsewhere in this pack describing pituitary hypoadrenocorticism and hypothyroidism following immunochemotherapy; also monitor for atypical/rapid progression patterns ("hyperprogression"), as reported in a separate case series involving pembrolizumab |
| Handling Protection | As an intravenous oncology biologic, handle per institutional biologic/oncology infusion protocols; standard cytotoxic-drug spill precautions are not applicable since pembrolizumab is not a conventional cytotoxic agent |

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (`safety.key_warnings`, `safety.contraindications`, and `safety.ddi` are all marked as data gaps in this evidence pack — see DG001, classified as Blocking severity.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Gingival Fibromatosis) has no supporting clinical trials or literature, and the evidence pack's own mechanistic analysis explicitly states there is no known biological link between PD-1 checkpoint blockade and this condition. Combined with a Blocking-severity data gap on TFDA-equivalent labelling (warnings/contraindications) and a "Not marketed" status with 0 authorisations, there is insufficient basis to advance this candidate.

**To proceed, the following is needed:**
- Product label warnings and contraindications (DG001, Blocking — required before any S1 safety screening can proceed)
- Verified mechanism of action data for Pembrolizumab (DG002)
- Any mechanistic or preclinical evidence specifically linking PD-1 blockade to gingival fibromatosis pathology (none currently identified)
- Note: a lower-ranked candidate in this same evidence pack, **Lung Hilum Carcinoma** (score 99.35%, Evidence Level L4, recommendation "Research Question"), shows substantially higher biological plausibility given Pembrolizumab's known NSCLC-related mechanism. Its current literature support is limited to two case reports describing adverse events (not efficacy) in other cancer types. It is worth confirming whether this reflects a genuine unstudied indication or a data-capture gap relative to Pembrolizumab's existing large-scale Phase 3 NSCLC evidence, before treating it as a novel repurposing signal.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

